programs, recap XX, ended Officer, begin our clinical open call, Officer, VittalVasista, us. overview Pakola, and Thanks an end our our results quarter the Medical the Good on afternoon, on as update up provide Chief of an At call provide financial today's a recent corporate then Patrick. our with pleased of line to March Steve goals. you, everyone. will for Financial highlights business XXXX. well our or will the continuing first will today's as questions. call for Thank update an we of joining Chief the again, I'm for Dr.
mission improve At to unmet REGENXBIO, through diseases that of developing our for we're curative therapy, is focused the and need. potential lives therapies significant have gene on
have We be continue leader NAV been with to thousands in therapeutics from therapy Technology AAV who of gene a with derived our patients dosed Platform.
diseases. the rare understanding gene for advance closely therapy work gene gene and regulatory There has therapy of in REGENXBIO endpoints. growing pricing accelerate particularly to partners of markers our with including industry viable models of progress been therapies, surrogate to the lately, continues development meaningful as and FDA clinical the help validation
leader gene Today, and strategy I'm track pleased Xx'XX X commercial XXXX. or remains REGENXBIO by pipeline to a stage programs for internal as therapy discuss on is we you products in AAV share with how from our pivotal our therapeutics into licensed advancing how
manufacturing in-house set gene in scalable, what's capabilities and as our therapeutics center advance innovation a commercial-ready therapy. continuing early experts AAV and our end-to-end possible research leader continue to of apart with batches development Our to us running our
delivery strategy. and routes specificity enhancing combinations, of optimizing and organs, for for presentations type such relevant and to as research AAV including and our this summary cell tissue areas expression, at announced therapeutics novel AAV other enhancer clinically proof-of-concept in therapeutics AAV targeting fact, around conference, in engineering and leadership next pipeline a of devices better which In optimizing we steps XX tissues capsids upcoming week, reflect of that the therapeutics promoter informs and ASGCT NAV
all AMD for and wet using trials AbbVie, with for update trials also as the significant originally subretinal global of our pivotal announced expansion including and age-related ATMOSPHERE eye collaboration in INDs and of degeneration collaboration care to the global ASCENT outlined delivery. in clinical or treatment agreement we ongoing the the AbbVie progress macular wet Today, transfer of
afternoon, financial pleased or to Medical our Steve an I'm recent provide corporate everyone. quarter well our March the first Vit clinical questions. Thank open business for Financial Good today's Vasista, Thanks up Dr. At on an call on update the for overview we our you, today's then Officer, a joining again, the continuing will will end the Chief and XXXX. ended highlights of an our Patrick. will XX, as us. line call of programs, goals. provide results recap Pakola, as with Officer, begin of Chief call, our update for
improve through lives and for REGENXBIO, need. gene to focused therapies on curative have mission significant is that we're potential therapy, unmet diseases of the At our developing
gene We continue dosed Platform. been our leader have therapeutics who with from to of be patients with NAV Technology a in therapy thousands derived AAV
pricing gene therapy our gene and of FDA industry particularly therapies, for endpoints. growing of development including clinical the to with continues markers therapy viable There closely understanding has work partners gene advance to in help validation the been lately, accelerate meaningful models as surrogate rare REGENXBIO regulatory the diseases. progress of and
with licensed therapeutics to how strategy and is stage advancing internal or I'm for pivotal from pleased commercial into track products remains XXXX. Today, programs AAV our gene X pipeline in a therapy REGENXBIO our how as share on by leader you discuss we Xx'XX
continue in-house commercial-ready research gene Our and center us advance batches as our AAV leader to development and our manufacturing early therapeutics set running possible experts to with end-to-end capabilities in scalable, innovation therapy. apart our continuing of what's a
clinically as around a type including NAV optimizing devices proof-of-concept organs, enhancing conference, that in delivery and research steps pipeline strategy. informs leadership therapeutics specificity capsids AAV and enhancer reflect for targeting ASGCT announced and AAV therapeutics we such cell to which promoter tissue week, and and combinations, routes optimizing expression, presentations tissues better engineering upcoming XX our next of AAV relevant of and other for areas therapeutics in this novel summary the at of fact, In
in global the update including our AbbVie, pivotal agreement macular in of originally the AbbVie the collaboration wet significant delivery. expansion all we using AMD trials eye of or progress wet treatment global ongoing Today, ASCENT to degeneration with age-related collaboration trials transfer care and for and announced outlined subretinal clinical the ATMOSPHERE INDs for of as also and
therapy FDA plans expanded half XXX. late guidance U.S. investigational our XXXX formerly RGX-XXX to through expected the I'll EMA milestones. trials known updates regulatory onetime support the as Our XXXX. way, involve by are to new plans for global with for has site ABBV-RGX-XXX. These and and new regulatory and enrollment also ATMOSPHERE in to submissions first gene of been renamed as global on, now from it the now ASCENT the And targets and refer The
our today's additional update to how XXX what the Steve the I the clear opportunity first, RGX-XXX. will are details, global is opportunity of XXX program. and I view and share clinical the value we our take further enhances frame optimizes where experience robustness we view to of make but to today, clinical the of want with want expansion global commercial the how for
X of retinal major the patients In injections of receive for vascular AMD, anti-VEGF eye standard wet every as in to the duration disease. XX every weeks to care, diseases require treatments, such current
some with and good, for emerging treatments are acting mechanisms. impact incremental anti-VEGF longer making not second-generation treatments patients First-generation an are anti-VEGF
retina and treatments. required clinical evidence evidence. trial they between the anti-VEGF frequency treated is And disease real-world that vision the to Patients, doctors control the undertreatment and anti-VEGF do tissue the and clinics first- both of shows Patients of However, doses. progression, impact improvements with cannot care. the of continue and of standard the second-generation vision. not us limitations leading the disease well -- consistently struggle lag controlled enough still emerging with to And current to be lost behind the damage the
onetime in and leadership address life see main to the gene wet our goal eye diseases major with diabetic worldwide. retinal and we're be our unmet to care footprint beyond AbbVie's the to other chronic and to and the Together developing conditions. vascular in significant bring we're forthcoming to announcement option the our in expand global retinal like global pleased with to expansion. this therapy in AMD retinopathy was treatment first vision XXX today's AbbVie, And U.S. patients coming partnering XXX need to A of with infrastructure leadership diseases
we're are position creating in opportunity for a worldwide. value patients We think great for to with we optimize the XXX today? Where
vascular the retinal have in opportunities largest expand program This involves X into II diabetic We retinal lead trials; ongoing X diseases. global several different AMD X and diseases. further clinical suprachoroidal X to pivotal clinical with delivery treatment trials, other including major and studying option subretinal indications, delivery for X and in onetime Phase retinopathy, devices for adjacent wet we're global; trials,
to designed Maryland, in innovation state-of-the-art Additionally, manufacturing as operational, standards. center, facility I therapy commercial here global before, which mentioned regulatory GMP manufacturing REGENXBIO's fully clinical and gene is is meet
is the is U.S. already Our trials with track And REGENX pivotal for that innovation at commercialization in platform lots to XXX. NAVXpress for center operating expand and to performance plan entire support as GMP manufacturing to planned the to bioreactors filings. to commercial with on level supply we XXX to the liter as innovation needed. regulatory process option an to use as produce In used being support scale the program liters XXXX, well commercial center up XXX X,XXX qualification produce material clinical manufacturing
the exposure subretinal well representing clinical our across have XXX years trials. both using been patient is dosed than totality tolerated. and method XXX delivery over to RGX-XXX of in total, patients the shows clinical suprachoroidal evidence summarize date treatment shared program, more experience, To of the The X in XXX of generally
responding our onetime X majority BCVA Long-term are in anti-VEGF stable with over XXX. has Patients injection-free. and studies in to patients follow-up a durability with burden shown treatment reduction meaningful generally of to of years subretinal improved
unsustainable shows the a the burden wet unmet due on need of real-world onetime addresses are currently potential care of to we of believe gene that higher XXX profile this level severely as undertreated with frequent high AMD could and these Now a to patients evidence standard of onetime therapy. transition injections. And patients treatment majority the
and the address Together XXX standard-of-care major with significant retinal interval to And in on emerging additional unmet patients. treatments. need for first therapeutic be onetime developing opportunity biosimilars diseases AbbVie, we're share market option longer there's from to vascular capitalize agents, to
what is calculated million be unmet need over billion opportunity a anti-VEGF to with market. XX potential a to worldwide This is reach with patients and already over global $XX high
low. is early retinopathy anti-VEGF to Additionally, today, frankly, utilization the like diseases treat diabetic of
estimated X decade supported next million loss. with $XX estimated a is as U.S. early to billion profile DR a in be right in patients have the to vision onetime the such treatment. and potential with a prevent the treatment X% patients as there high. of potential to care burden become of XXX is treated believe retinopathy We is intravitreal Less with early injection single disease are diabetic a standard injections. in-office treatment for The new that a alone, early than market An DR global treatment for
the get So turn that, Steve Steve? into so pipeline depth on and also and greater our disease I'm and our with he updates. going progress to can over call progress rare discuss clinical to XXX
